Prevalence and features of osteoporosis in the French general population: The Instant study

Joint Bone Spine

Volumn 76, Issue 4, 2009, Pages 394-400

  Lespessailles, Éric ^a   Cotté, François Emery ^b   Roux, Christian ^c   Fardellone, Patrice ^d   Mercier, Florence ^e   Gaudin, Anne Françoise ^b  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b GLAXOSMITHKLINE   (France)

^c université Paris Cité   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e STAT PROCESS   (France)

Author keywords

Epidemiology; Fracture; Osteoporosis; Risk factors

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONSULTATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; FRAGILITY FRACTURE; FRANCE; HUMAN; INCIDENCE; INTERVIEW; LIMB FRACTURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENOPAUSE; OSTEOPOROSIS; PILL; POPULATION; PREVALENCE; RANDOM SAMPLE; RISK FACTOR; RISK MANAGEMENT; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; EPIDEMIOLOGIC STUDIES; FEMALE; FRACTURES, BONE; FRANCE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE;

EID: 67649824120     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.10.008     Document Type: Article

References (48)

1. Wehren L.E., and Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep 1 (2003) 78-85
2. Kanis J.A., and Gluer C.C. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11 (2000) 192-202
3. HAS. Ostéodensitométrie [absorbimétrie osseuse] sur 2 sites par méthode biphotonique; 2006. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/osteodensitometrie_rapport.pdf
4. Borgstrom F., Zethraeus N., Johnell O., et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17 (2006) 637-650
5. Maravic M., Le Bihan C., Landais P., et al. Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16 (2005) 1475-1480
6. Briançon D., de Gaudemar J.B., and Forestier R. Management of osteoporosis in women with peripheral osteoporotic fractures after 50 years of age: a study of practices. Joint Bone Spine 71 (2004) 128-130
7. Blotman F., Cortet B., Hilliquin P., et al. Characterisation of patients with postmenopausal osteoporosis in French primary healthcare. Drugs Aging 24 (2007) 603-614
8. National Institute of Health. Osteoporosis prevention, diagnosis, and therapy. J Am Med Assoc 285 (2001) 785-795
9. Sornay-Rendu E., Munoz F., Garnero P., et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20 (2005) 1813-1819
10. Grados F., Marcelli C., Dargent-Molina P., et al. Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study. Bone 34 (2004) 362-367
11. Roux C., Fardelllone P., Lespessailles E., et al. Prevalence of risk factors for referring post-menopausal women for bone densitometry. The INSTANT study. Joint Bone Spine 75 (2008) 702-707
12. Ware Jr. J., Kosinski M., and Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34 (1996) 220-233
13. Petrella R.J., and Jones T.J. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care?. BMC Fam Pract 7 (2006) 31
14. Panneman M.J., Lips P., Sen S.S., et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15 (2004) 120-124
15. Hooven F., Gehlbach S.H., Pekow P., et al. Follow-up treatment for osteoporosis after fracture. Osteoporos Int 16 (2005) 296-301
16. Gardner M.J., Flik K.R., Mooar P., et al. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84 A (2002) 1342-1348
17. Cramer J.A., Lynch N.O., Gaudin A.F., et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28 (2006) 1686-1694
18. McCombs J.S., Thiebaud P., McLaughlin-Miley C., et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
19. Papaioannou A., Ioannidis G., Adachi J.D., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14 (2003) 808-813
20. Cortet B., and Benichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis?. Joint Bone Spine 73 (2006) e1-e7
21. Lespessailles E. A forgotten challenge when treating osteoporosis: getting patients to take their meds. Joint Bone Spine 74 (2007) 7-8
22. Boonen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16 (2005) 1291-1298
23. Nguyen N.D., Eisman J.A., and Nguyen T.V. Anti-hip fracture efficacy of bisphosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21 (2006) 340-349
24. Espallargues M., Sampietro-Colom L., Estrada M.D., et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 12 (2001) 811-822
25. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332 (1995) 767-773
26. Albrand G., Munoz F., Sornay-Rendu E., et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32 (2003) 78-85
27. Pouilles J.M., Tremollieres F., Bonneu M., et al. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 9 (1994) 311-315
28. van Der Voort D.J., van Der Weijer P.H., and Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 14 (2003) 525-530
29. Gallagher J.C. Effect of early menopause on bone mineral density and fractures. Menopause 14 (2007) 567-571
30. Dargent-Molina P., Favier F., Grandjean H., et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 348 (1996) 145-149
31. Felson D.T., Anderson J.J., Hannan M.T., et al. Impaired vision and hip fracture. The Framingham study. J Am Geriatr Soc 37 (1989) 495-500
32. Ivers R.Q., Norton R., Cumming R.G., et al. Visual impairment and risk of hip fracture. Am J Epidemiol 152 (2000) 633-639
33. Ivers R.Q., Cumming R.G., Mitchell P., et al. Visual risk factors for hip fracture in older people. J Am Geriatr Soc 51 (2003) 356-363
34. Lord S.R. Visual risk factors for falls in older people. Age Ageing 35 Suppl. 2 (2006) ii42-ii45
35. Harwood R.H., Foss A.J., Osborn F., et al. Falls and health status in elderly women following first eye cataract surgery: a randomised controlled trial. Br J Ophthalmol 89 (2005) 53-59
36. Ray W.A., Griffin M.R., Schaffner W., et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 316 (1987) 363-369
37. Takkouche B., Montes-Martinez A., Gill S.S., et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 30 (2007) 171-184
38. Lagnaoui R., Depont F., Fourrier A., et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60 (2004) 523-529
39. Wagner A.K., Ross-Degnan D., Gurwitz J.H., et al. Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med 146 (2007) 96-103
40. Johansson C., and Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas 24 (1996) 97-106
41. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
42. Cooper C., Atkinson E.J., Jacobsen S.J., et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137 (1993) 1001-1005
43. McFarlane S.I., Muniyappa R., Shin J.J., et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?. Endocrine 23 (2004) 1-10
44. Yao Z., Lafage-Proust M.H., Plouet J., et al. Increase of both angiogenesis and bone mass in response to exercise depends on VEGF. J Bone Miner Res 19 (2004) 1471-1480
45. Tanko L.B., Christiansen C., Cox D.A., et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20 (2005) 1912-1920
46. Chen Z., Kooperberg C., Pettinger M.B., et al. Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause 11 (2004) 264-274
47. Ward K.D., and Klesges R.C. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 68 (2001) 259-270
48. Christiansen C., and Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1 (1990) 7-13